Automate Your Wheel Strategy on PFE
With Tiblio's Option Bot, you can configure your own wheel strategy including PFE - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol PFE
- Rev/Share 11.0121
- Book/Share 16.3822
- PB 1.6518
- Debt/Equity 0.0
- CurrentRatio 0.0
- ROIC 0.0
- MktCap 153855246357.0
- FreeCF/Share 0.8045
- PFCF 33.6516
- PE 19.7909
- Debt/Assets 0.0
- DivYield 0.0636
- ROE 0.0852
- Rating B
- Score 3
- Recommendation Neutral
- P/E Score 3
- DCF Score 4
- P/B Score 4
- D/E Score 1
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Initiation | PFE | Barclays | -- | Underweight | -- | $25 | Feb. 20, 2026 |
| Downgrade | PFE | Daiwa Securities | Outperform | Neutral | -- | $27 | Feb. 12, 2026 |
| Resumed | PFE | UBS | -- | Neutral | -- | $25 | Jan. 7, 2026 |
| Resumed | PFE | Citigroup | -- | Neutral | -- | $26 | Dec. 2, 2025 |
| Initiation | PFE | Scotiabank | -- | Sector Outperform | -- | $30 | Nov. 13, 2025 |
| Initiation | PFE | Cantor Fitzgerald | -- | Neutral | -- | $24 | April 22, 2025 |
| Resumed | PFE | BofA Securities | -- | Neutral | -- | $29 | Dec. 10, 2024 |
| Initiation | PFE | Bernstein | -- | Market Perform | -- | $32 | Oct. 17, 2024 |
News
My 5 Favorite Dividend Stocks to Buy Right Now
Published: February 22, 2026 by: The Motley Fool
Sentiment: Positive
It may be the right time for investors to start playing a little less offense and a little more defense. The best defensive names, however, are shares of businesses that continue to generate cash flow regardless of the economic environment.
Read More
AstraZeneca vs. Pfizer: Which Pharma Giant Has the Edge in 2026?
Published: February 20, 2026 by: Zacks Investment Research
Sentiment: Positive
AZN's stronger growth outlook and 2030 revenue target may outshine PFE's yield and cheaper valuation.
Read More
Pfizer Targets Long-Term Oncology Growth Amid Competitive Pressure
Published: February 19, 2026 by: Zacks Investment Research
Sentiment: Negative
PFE's oncology sales rose 8% in 2025 as Padcev, Lorbrena and new launches offset Ibrance declines.
Read More
Top High-Yield Stocks to Double Up on Right Now
Published: February 19, 2026 by: The Motley Fool
Sentiment: Positive
Pfizer has made the investments needed to get its drug pipeline back on track. United Parcel Service's turnaround effort is starting to show progress.
Read More
Is There 25% Downside For Pfizer Stock?
Published: February 18, 2026 by: Forbes
Sentiment: Negative
Our comprehensive evaluation suggests that divesting from Pfizer stock (NYSE: PFE) may be the most prudent course of action. Our analysis points a bearish outlook on the stock, with a plausible price target of $20.
Read More
Pfizer: Recovery Isn't Over, Battered Valuation Still Discounts Its Turnaround Game
Published: February 18, 2026 by: Seeking Alpha
Sentiment: Positive
Despite the recent recovery, I explain why Pfizer remains materially undervalued, trading near 10-year lows with a 6.4% dividend yield. Pfizer faces multi-year headwinds from loss of exclusivity and COVID franchise decline, but management highlights transformative M&A and pipeline optionality. Obesity drugs, particularly via Metsera, represent a potential $150B TAM, though market skepticism persists until Phase III data matures.
Read More
Pfizer to collect $29 million from SEC case against Steven A. Cohen hedge fund
Published: February 10, 2026 by: Reuters
Sentiment: Neutral
Pfizer agreed to accept $29 million to resolve a dispute with the U.S. Securities and Exchange Commission stemming from the regulator's 2013 insider trading settlement with billionaire Steven A. Cohen's former hedge fund SAC Capital Management.
Read More
Pfizer Inc. (PFE) Is a Trending Stock: Facts to Know Before Betting on It
Published: February 10, 2026 by: Zacks Investment Research
Sentiment: Positive
Zacks.com users have recently been watching Pfizer (PFE) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
Read More
Should You Buy, Sell or Hold Pfizer Stock After a Lukewarm Q4?
Published: February 09, 2026 by: Zacks Investment Research
Sentiment: Positive
PFE beat Q4 estimates, but weak COVID sales and soft 2026 guidance kept shares muted as investors weigh pipeline strength against looming headwinds.
Read More
3 High-Yield Dividend Stocks Perfect For Retirees
Published: February 06, 2026 by: 24/7 Wall Street
Sentiment: Positive
What does a successful retirement look like? If it means financial security through steady income sources, then you can get there with the help of high-yield dividend stocks.
Read More
Healthy Returns: Pfizer execs chart out obesity strategy after encouraging drug data
Published: February 06, 2026 by: CNBC
Sentiment: Positive
Pfizer made one thing clear this week: It's officially back in the obesity race.
Read More
Pfizer Bets Big on Obesity and Oncology With 2026 Pipeline Push
Published: February 06, 2026 by: Zacks Investment Research
Sentiment: Neutral
PFE is betting on obesity and oncology in 2026, lining up 20 pivotal studies after $9B in 2025 M&A.
Read More
Eli Lilly Soared by 39% in 2025, but Here's Another Healthcare Stock to Buy in 2026
Published: February 04, 2026 by: The Motley Fool
Sentiment: Positive
Eli Lilly has leading products in the GLP-1 space, with plans to bring pill versions of its weight loss shots to market. Pfizer is playing catch-up in the GLP-1 space, but it has a long history of innovation.
Read More
Pfizer Inc. (PFE) Q4 2025 Earnings Call Transcript
Published: February 03, 2026 by: Seeking Alpha
Sentiment: Neutral
Pfizer Inc. (PFE) Q4 2025 Earnings Call Transcript
Read More
Pfizer: Messy Q4 Earnings Mask An Improving Business
Published: February 03, 2026 by: Seeking Alpha
Sentiment: Positive
Pfizer Inc. earns a Buy rating as the market overreacts to Q4's non-cash loss and conservative 2026 guidance, overlooking underlying operational strength. Excluding COVID-19 products, PFE posted 9% YoY growth, driven by oncology, signaling a successful pivot away from declining pandemic franchises. Patent cliffs—Xeljanz in 2026, Eliquis in 2028—pose risks, but PFE is aggressively advancing a 102-candidate pipeline targeting oncology, obesity, and migraine.
Read More
Pfizer Stock Slides Despite Q4 Earnings Beat and New Obesity Drug Data
Published: February 03, 2026 by: Zacks Investment Research
Sentiment: Negative
PFE shares fall even after Q4 earnings beat on COVID product declines and muted investor reaction to new obesity drug data.
Read More
Silver Surges Over 15%; Pfizer Earnings Top Views
Published: February 03, 2026 by: Benzinga
Sentiment: Neutral
U.S. stocks traded lower midway through trading, with the Nasdaq Composite falling more than 1% on Tuesday.
Read More
Pfizer Q4 Earnings Review: This Classic Value Trap Remains As Tempting As Ever
Published: February 03, 2026 by: Seeking Alpha
Sentiment: Negative
Pfizer reported Q4 and FY2025 revenues and EPS above expectations, but core revenues declined due to falling COVID product sales. Despite a 6.5% dividend yield and low valuation multiples, PFE remains a value trap as share price performance lags and patent expiries loom. Recent M&A, including Seagen and Metsera, must deliver as COVID windfall fades and major assets like Eliquis and Prevnar approach patent cliffs.
Read More
Pfizer, Merk report Q4 results: Citi's Geoff Meacham on key takeaways
Published: February 03, 2026 by: CNBC Television
Sentiment: Neutral
Geoff Meacham, Citi Research head of U.S. pharmaceuticals and biotechnology, joins 'Squawk Box' to break down the quarterly earnings results of Pfizer and Merck.
Read More
2 Pharma Stocks React to Quarterly Results, Guidance
Published: February 03, 2026 by: Schaeffers Research
Sentiment: Negative
Pfizer Inc (NYSE:PFE) shares are down 3.2% to trade at $25.40 at last check, despite surpassing earnings and revenue expectations for the fourth quarter.
Read More
Pfizer (PFE) Q4 Earnings: Taking a Look at Key Metrics Versus Estimates
Published: February 03, 2026 by: Zacks Investment Research
Sentiment: Neutral
While the top- and bottom-line numbers for Pfizer (PFE) give a sense of how the business performed in the quarter ended December 2025, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
Read More
Pfizer beats Q4 profit estimates despite COVID-19 sales decline
Published: February 03, 2026 by: Proactive Investors
Sentiment: Neutral
Pfizer Inc (NYSE:PFE, XETRA:PFE) reported fourth-quarter and full-year 2025 results on Tuesday, exceeding analyst expectations on adjusted earnings even as sales of its COVID-19 products fell. The pharmaceutical company's beat on profit wasn't enough to offset concerns about declining COVID-19 revenue and future growth uncertainties, with shares dropping 4.3% on Tuesday morning in New York.
Read More
Pfizer (PFE) Q4 Earnings and Revenues Beat Estimates
Published: February 03, 2026 by: Zacks Investment Research
Sentiment: Positive
Pfizer (PFE) came out with quarterly earnings of $0.66 per share, beating the Zacks Consensus Estimate of $0.57 per share. This compares to earnings of $0.63 per share a year ago.
Read More
Pfizer says once-a-month weight-loss drug works as it forecasts profit decline
Published: February 03, 2026 by: Market Watch
Sentiment: Neutral
Pfizer on Tuesday hailed a study of a weight-loss-drug candidate while forecasting a profit decline due to the impact of the Trump administration's policies on pricing and tariffs.
Read More
Pfizer Sales Fall on Continued Lower Covid-19 Drug Demand
Published: February 03, 2026 by: WSJ
Sentiment: Negative
Pfizer reported lower fourth-quarter sales as demand for its Covid-19 vaccine and antiviral drug continued to decline.
Read More
Pfizer says obesity injection shows promise as monthly treatment in mid-stage trial
Published: February 03, 2026 by: CNBC
Sentiment: Positive
Pfizer said its experimental obesity drug, which it acquired through Metsera, drove solid weight loss when taken once a month in a mid-stage trial. The data offer early evidence that the injection can be administered less frequently than existing drugs without sacrificing efficacy.
Read More
Pfizer Stock Falls After Solid Earnings. What's Troubling Wall Street.
Published: February 03, 2026 by: Barrons
Sentiment: Negative
Pfizer also releases positive top-line results from a trial for its injectable GLP-1 receptor agonist in adults with obesity.
Read More
Pfizer beats quarterly estimates despite Covid product decline, reaffirms modest outlook
Published: February 03, 2026 by: CNBC
Sentiment: Neutral
Pfizer reported fourth-quarter revenue and earnings that topped estimates even amid dwindling demand for its Covid products. The pharmaceutical giant reaffirmed the modest 2026 outlook that rattled investors in December.
Read More
Pfizer's experimental drug shows up to 12.3% weight loss in mid-stage trial
Published: February 03, 2026 by: Reuters
Sentiment: Positive
Pfizer said on Tuesday its experimental obesity drug, which it acquired through the Metsera deal, showed up to 12.3% weight loss in patients without diabetes in a mid-stage trial.
Read More
Pfizer Reports Solid Full-Year 2025 Results And Reaffirms 2026 Guidance
Published: February 03, 2026 by: Business Wire
Sentiment: Neutral
NEW YORK--(BUSINESS WIRE)--PFE Q4 2025 Earnings Release.
Read More
About Pfizer Inc. (PFE)
- IPO Date 1972-06-01
- Website https://www.pfizer.com
- Industry Drug Manufacturers - General
- CEO Albert Bourla
- Employees 81000